Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: A randomized controlled pilot trial
Carvalho JTG, Schneider M, Cuppari L, Grabulosa CC, T Aoike D, Q Redublo BM, C Batista M, Cendoroglo M, Maria Moyses R, Dalboni MA
PloS one · 39 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People, plus animal or lab work
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
- Government
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2017-06-30 · PLoS One · vol. 12 · issue 6 · p. e0179540
- Publisher
- Public Library of Science
- Cited
- 49 citations · more than 94% of similar papers · 3.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 41 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Vitamin D Research Studies · Vitamin C and Antioxidants Research · Therapeutic Uses of Natural Elements
- Keywords
- CYP24A1, Calcitriol receptor, Vitamin D and neurology, Cholecalciferol, Internal medicine, Endocrinology, Medicine, Vitamin, vitamin D deficiency, TLR9, Pharmacology, Biology, Gene expression, Biochemistry
- MeSH
- humans, uremia, inflammation, cholecalciferol, 25-hydroxyvitamin d3 1-alpha-hydroxylase, vitamin d, receptors, calcitriol, inflammation mediators, cytokines, placebos, case-control studies, pilot projects, double-blind method, toll-like receptors, vitamin d3 24-hydroxylase
10 authors
From BR
- José Tarcísio Giffoni de Carvalho · correspondingUniversidade Federal de São Paulo
- Marion SchneiderUniversidade Federal de São Paulo
- Lílian CuppariUniversidade Federal de São Paulo
- Caren Cristina GrabulosaUniversidade Federal de São Paulo
- Danilo Takashi AoikeUniversidade Federal de São Paulo
- Beata Marie Quinto RedubloUniversidade Federal de São Paulo
Abstract
It has been reported that vitamin D regulates the immune system. However, whether vitamin D repletion modulates inflammatory responses in lymphocytes from dialysis patients is unclear. In the clinical trial, thirty-two (32) dialysis patients with 25 vitamin D ≤ 20ng/mL were randomized to receive either supplementation of cholecalciferol 100,000 UI/week/3 months (16 patients) or placebo (16 patients). In the in vitro study, B and T lymphocytes from 12 healthy volunteers (HV) were incubated with or without uremic serum in the presence or absence of 25 or 1,25 vitamin D. We evaluated the intracellular expression of IL-6, IFN-γ TLR7, TLR9, VDR, CYP27b1 and CYP24a1 by flow cytometry. We observed a reduction in the expression of TLR7, TLR9, INF-γ and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Uremic serum increased the intracellular expression of IL-6, IFN-γ, TLR7, TLR9, VDR, CYP27b1 and CYP24a1. Treatment with 25 or 1,25 vitamin D decreased IL-6 and TLR9. CYP24a1 silencing plus treatment with 25 and/or 1,25 vitamin D had an additional reduction effect on IL-6, IFN-γ, TLR7 and TLR9 expression. This is the first study showing that cholecalciferol repletion has an anti-inflammatory effect and improves vitamin D intracellular regulatory enzymes on lymphocytes from dialysis patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.